Dr. Reddy's Laboratories Ltd. (RDY)

NYSE - NYSE Real Time Price. Currency in USD
48.44+0.08 (+0.17%)
As of 1:25 PM EDT. Market open.
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close48.36
Bid48.45 x 200
Ask48.48 x 200
Day's Range48.28 - 49.59
52wk Range40.67 - 66.68
1y Target EstN/A
Market Cap8.05B
P/E Ratio (ttm)36.84
Avg Vol (3m)315,361
Dividend & Yield0.30 (0.65%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Business Wire3 hours ago

    Dr. Reddy's Laboratories Announces New Strategic Deal with Gland Pharma in the U.S. Market

    Dr. Reddy’s Laboratories Ltd. announced today that it has entered into a strategic collaboration with Gland Pharma, a globally recognized developer and manufacturer of sterile dosage forms, to market and distribute a diverse portfolio of eight injectable Abbreviated New Drug Applications .

  • Dr. Reddy's (RDY) Earnings & Revenues Decline Y/Y in Q2
    Zacks4 hours ago

    Dr. Reddy's (RDY) Earnings & Revenues Decline Y/Y in Q2

    Dr. Reddy's Laboratories Ltd. (RDY) reported second-quarter fiscal 2017 earnings per American Depositary Share (ADS) of 27 cents, down 57.1% year over year.

  • Barrons.com23 hours ago

    What Gives? Dr. Reddy's Shares Jump 6% Despite Earnings Miss

    Earlier today, India’s second-largest drug maker, reported a fiscal second quarter quarterly profit that was below analysts' estimates due to a drop in sales, mainly in emerging markets. As Reuters reported: Net profit for the July-September quarter was 3.09 billion rupees ($46.20 million), while analysts, on average, had expected a profit of 3.5 billion rupees, according to Thomson Reuters data. Sales fell in most of Dr Reddy's markets, especially the emerging market countries that include Russia and Romania, where they were down 27 percent in value terms.